Literature DB >> 6404496

HLA antigens and acetylcholine receptor antibodies in penicillamine induced myasthenia gravis.

M I Garlepp, R L Dawkins, F T Christiansen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6404496      PMCID: PMC1547837          DOI: 10.1136/bmj.286.6375.1442-a

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


× No keyword cloud information.
  5 in total

1.  Binding affinities of anti-acetylcholine receptor autoantibodies in myasthenia gravis.

Authors:  J J Bray; D B Drachman
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422

2.  The diagnostic significance of autoantibodies to the acetylcholine receptor.

Authors:  M J Garlepp; P H Kay; R L Dawkins
Journal:  J Neuroimmunol       Date:  1982-12       Impact factor: 3.478

3.  Cross-reactivity of anti-acetylcholine receptor autoantibodies.

Authors:  M J Garlepp; P H Kay; R L Dawkins; R C Bucknall; A Kemp
Journal:  Muscle Nerve       Date:  1981 Jul-Aug       Impact factor: 3.217

4.  Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles.

Authors:  A Vincent; J Newsom-Davis
Journal:  Clin Exp Immunol       Date:  1982-08       Impact factor: 4.330

5.  Acetylcholine receptor antibody characteristics in myasthenia gravis. II. Patients with penicillamine-induced myasthenia or idiopathic myasthenia of recent onset.

Authors:  A Vincent; J Newsom-Davis
Journal:  Clin Exp Immunol       Date:  1982-08       Impact factor: 4.330

  5 in total
  2 in total

Review 1.  Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.

Authors:  Rebecca Pavlos; Simon Mallal; David Ostrov; Yuri Pompeu; Elizabeth Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Jan-Feb

Review 2.  Neurology of rheumatologic disorders.

Authors:  Amre Nouh; Olimpia Carbunar; Sean Ruland
Journal:  Curr Neurol Neurosci Rep       Date:  2014-07       Impact factor: 6.030

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.